Navigation Links
Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
Date:12/17/2009

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors. Both surveyed physicians and patients favor agents with excellent glucose lowering ability and physicians in particular say the most influential attribute would be if an agent could reduce HbA1c levels by two percent.

"Physicians we surveyed also tell us that they prefer an agent with an excellent safety profile, which is not surprising given the cardiovascular safety concerns associated with GlaxoSmithKline's Avandia and the more recent pancreatitis association with both Amylin/Eli Lilly's Byetta and Merck's Januvia," stated Nicole Westphal, Ph.D., analyst and product manager at Decision Resources. "For surveyed type 2 diabetes patients, an emerging therapy with disease modifying potential (one that improves the function of insulin producing cells) is also highly desirable."

The new report entitled Brand Perceptions in Noninsulin Antidiabetics also identifies segments of physicians and type 2 diabetes patients that each uses a different mix of criteria to make treatment decisions. The physician segment comprised of young, urban, weight-conscious specialists favor Byetta and will likely drive adoption of new GLP-1 analogues such as, Novo Nordisk/Scios's Victoza and Alkermes/Amylin/Eli Lilly's Byetta LAR. Given this segment's reliance on clinical evidence to drive decisions, this physician segment is an ideal target for companies developing novel drugs.

"The majority of surveyed physicians predict that out of these two agents, Byetta LAR will have the most significant impact on type 2 diabetes treatment, likely because of their familiarity with and comfort prescribing Byetta (Byetta LAR has the same active molecule as Byetta) and their opinion that Byetta LAR (once-weekly injection) offers substantial dosing advantage over Victoza (once-daily injection)," added Dr. Westphal.

The report contains primary research based on a survey of 148 U.S. physicians and 336 U.S. patients. Key brands included in the primary research consist of Byetta; Takeda's Actos, ACTOplus met and Duetact; GlaxoSmithKline's Avandia, Avandamet and Avandaryl; Merck's Januvia and Janumet; and Bristol-Myers Squibb/AstraZeneca/Otsuka's Onglyza.

About Brand Perception Series

Decision Resources' Brand Perception Series quantitatively analyzes physician and patient brand perception of current and emerging therapies and identifies key physician and patient segments to help clients identify high opportunity targets. The findings are driven by extensive primary research and offer clients an unbiased, comprehensive, cost-effective solution to understanding the full competitive brand landscape.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
2. $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers
3. Russias Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
4. Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
5. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
6. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
7. Burton Medicals New Diagnostic Examination Light, the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life
8. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
9. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
10. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
11. Abbott Cuts Use of Oil and Coal by 35 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Miami Dental ... implants to their Miami dental office. Beginning in January, Miami Dental Specialists will ... Miami Dental Specialists are the first office to be chosen by the dental implant ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, ... Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health ... therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism Spectrum Center (CCASC) ... is to provide a night of fun for teens with and without special needs to ... welcomed and included at the event. The dance will take place on Saturday, Feb. 13 ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative dentistry, ... of dental decay. With the recent approval by the FDA, there is a now ... similar to fluoride varnish, SDF is very simple and quick to apply. The application ...
(Date:2/11/2016)... ... February 11, 2016 , ... SPH Analytics ... action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its primary care ... healthcare system. Details of the contract were not disclosed. , As the healthcare ...
Breaking Medicine News(10 mins):